These two biotech companies are big established players rather than exciting start-ups, which may help explain why they find themselves underappreciated by investors right now. But these two firms have massive cash flows and promising pipelines – including a hormone therapy for women with endometriosis-linked pain that could receive FDA approval very soon. CLICK HERE.
